Loading…
Nanotechnology in Tuberculosis: State of the Art and the Challenges Ahead
Tuberculosis (TB) remains as the second most-deadly infection right behind the HIV/AIDS. Actually, in 2016, TB incidence was estimated in 10.4 million cases. Although an efficient and low-cost TB pharmacotherapy has been available for the last 50 years, the development of multi- and extra-drug-resis...
Saved in:
| Published in: | Pharmaceutical research 2018-11, Vol.35 (11), p.213-22, Article 213 |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c439t-265a7c5dc192266502b74284e155bcd22e1b9b56fbbfe0002c4484897f022f933 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c439t-265a7c5dc192266502b74284e155bcd22e1b9b56fbbfe0002c4484897f022f933 |
| container_end_page | 22 |
| container_issue | 11 |
| container_start_page | 213 |
| container_title | Pharmaceutical research |
| container_volume | 35 |
| creator | Grotz, Estefania Tateosian, Nancy Amiano, Nicolas Cagel, Maximiliano Bernabeu, Ezequiel Chiappetta, Diego A. Moretton, Marcela A. |
| description | Tuberculosis (TB) remains as the second most-deadly infection right behind the HIV/AIDS. Actually, in 2016, TB incidence was estimated in 10.4 million cases. Although an efficient and low-cost TB pharmacotherapy has been available for the last 50 years, the development of multi- and extra-drug-resistant
Mycobacterium tuberculosis
(Mtb) strains has put on the spot the necessity of improved TB regimens. In this framework, this review article presents the main relevant research outcomes of nanotechnology in TB. The novel delivery systems for antituberculosis drugs have been discussed. Moreover, the active-targeted nanomedicines to the Mtb reservoirs enlighten the possibility to eradicate low-replicant mycobacteria and diminish latent TB. Finally, we present an overview of the TB socio-economic impact and the cost-related features of TB regimens associated with the use of nanoformulations. |
| doi_str_mv | 10.1007/s11095-018-2497-z |
| format | article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_journals_2110154837</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A724210136</galeid><sourcerecordid>A724210136</sourcerecordid><originalsourceid>FETCH-LOGICAL-c439t-265a7c5dc192266502b74284e155bcd22e1b9b56fbbfe0002c4484897f022f933</originalsourceid><addsrcrecordid>eNp1kUtPxCAUhYnR6Pj4AW5ME9dVoFDA3WTiKzG6UBN3hNLLTCedotAuZn696IwaEw0LCHzn3ss5CB0TfEYwFueREKx4jonMKVMiX22hEeGiyBVmL9tohAVluRSM7KH9GOcYY0kU20V7BaaFJKUcodt70_ke7KzzrZ8us6bLnoYKgh1aH5t4kT32pofMu6yfQTYOfWa6-vM8mZm2hW4KMRvPwNSHaMeZNsLRZj9Az1eXT5Ob_O7h-nYyvsstK1Sf05IbYXltiaK0LDmmlWBUMiCcV7amFEilKl66qnKQJqaWMcmkEg5T6lRRHKDTdd3X4N8GiL2e-yF0qaWmyQ_CmSzEDzU1Leimc74Pxi6aaPU4uUITWJSJOvuDSquGRWN9B65J978EZC2wwccYwOnX0CxMWGqC9Ucmep2JTpnoj0z0KmlONgMP1QLqb8VXCAmgayCmp2Ro-PnR_1XfAWHtk8s</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2110154837</pqid></control><display><type>article</type><title>Nanotechnology in Tuberculosis: State of the Art and the Challenges Ahead</title><source>Springer Nature</source><creator>Grotz, Estefania ; Tateosian, Nancy ; Amiano, Nicolas ; Cagel, Maximiliano ; Bernabeu, Ezequiel ; Chiappetta, Diego A. ; Moretton, Marcela A.</creator><creatorcontrib>Grotz, Estefania ; Tateosian, Nancy ; Amiano, Nicolas ; Cagel, Maximiliano ; Bernabeu, Ezequiel ; Chiappetta, Diego A. ; Moretton, Marcela A.</creatorcontrib><description>Tuberculosis (TB) remains as the second most-deadly infection right behind the HIV/AIDS. Actually, in 2016, TB incidence was estimated in 10.4 million cases. Although an efficient and low-cost TB pharmacotherapy has been available for the last 50 years, the development of multi- and extra-drug-resistant
Mycobacterium tuberculosis
(Mtb) strains has put on the spot the necessity of improved TB regimens. In this framework, this review article presents the main relevant research outcomes of nanotechnology in TB. The novel delivery systems for antituberculosis drugs have been discussed. Moreover, the active-targeted nanomedicines to the Mtb reservoirs enlighten the possibility to eradicate low-replicant mycobacteria and diminish latent TB. Finally, we present an overview of the TB socio-economic impact and the cost-related features of TB regimens associated with the use of nanoformulations.</description><identifier>ISSN: 0724-8741</identifier><identifier>EISSN: 1573-904X</identifier><identifier>DOI: 10.1007/s11095-018-2497-z</identifier><identifier>PMID: 30238168</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Acquired immune deficiency syndrome ; AIDS ; Animals ; Antitubercular agents ; Antitubercular Agents - administration & dosage ; Antitubercular Agents - chemistry ; Antitubercular Agents - therapeutic use ; B cells ; Biochemistry ; Biomedical and Life Sciences ; Biomedical Engineering and Bioengineering ; Biomedicine ; Development and progression ; Drug delivery ; Drug Delivery Systems - methods ; Drug Discovery - methods ; Drug resistance ; Drug Resistance, Bacterial ; Economic impact ; Expert Review ; Health aspects ; HIV ; Human immunodeficiency virus ; Humans ; Liposomes - chemistry ; Medical Law ; Micelles ; Mycobacterium tuberculosis - drug effects ; Nanomedicine - methods ; Nanomedicine for Infectious Diseases ; Nanoparticles - chemistry ; Nanotechnology ; Nanotechnology - methods ; Patient compliance ; Pharmacology/Toxicology ; Pharmacy ; Tuberculosis ; Tuberculosis - drug therapy ; Tuberculosis - pathology</subject><ispartof>Pharmaceutical research, 2018-11, Vol.35 (11), p.213-22, Article 213</ispartof><rights>Springer Science+Business Media, LLC, part of Springer Nature 2018</rights><rights>COPYRIGHT 2018 Springer</rights><rights>Pharmaceutical Research is a copyright of Springer, (2018). All Rights Reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c439t-265a7c5dc192266502b74284e155bcd22e1b9b56fbbfe0002c4484897f022f933</citedby><cites>FETCH-LOGICAL-c439t-265a7c5dc192266502b74284e155bcd22e1b9b56fbbfe0002c4484897f022f933</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,27905,27906</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30238168$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Grotz, Estefania</creatorcontrib><creatorcontrib>Tateosian, Nancy</creatorcontrib><creatorcontrib>Amiano, Nicolas</creatorcontrib><creatorcontrib>Cagel, Maximiliano</creatorcontrib><creatorcontrib>Bernabeu, Ezequiel</creatorcontrib><creatorcontrib>Chiappetta, Diego A.</creatorcontrib><creatorcontrib>Moretton, Marcela A.</creatorcontrib><title>Nanotechnology in Tuberculosis: State of the Art and the Challenges Ahead</title><title>Pharmaceutical research</title><addtitle>Pharm Res</addtitle><addtitle>Pharm Res</addtitle><description>Tuberculosis (TB) remains as the second most-deadly infection right behind the HIV/AIDS. Actually, in 2016, TB incidence was estimated in 10.4 million cases. Although an efficient and low-cost TB pharmacotherapy has been available for the last 50 years, the development of multi- and extra-drug-resistant
Mycobacterium tuberculosis
(Mtb) strains has put on the spot the necessity of improved TB regimens. In this framework, this review article presents the main relevant research outcomes of nanotechnology in TB. The novel delivery systems for antituberculosis drugs have been discussed. Moreover, the active-targeted nanomedicines to the Mtb reservoirs enlighten the possibility to eradicate low-replicant mycobacteria and diminish latent TB. Finally, we present an overview of the TB socio-economic impact and the cost-related features of TB regimens associated with the use of nanoformulations.</description><subject>Acquired immune deficiency syndrome</subject><subject>AIDS</subject><subject>Animals</subject><subject>Antitubercular agents</subject><subject>Antitubercular Agents - administration & dosage</subject><subject>Antitubercular Agents - chemistry</subject><subject>Antitubercular Agents - therapeutic use</subject><subject>B cells</subject><subject>Biochemistry</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedical Engineering and Bioengineering</subject><subject>Biomedicine</subject><subject>Development and progression</subject><subject>Drug delivery</subject><subject>Drug Delivery Systems - methods</subject><subject>Drug Discovery - methods</subject><subject>Drug resistance</subject><subject>Drug Resistance, Bacterial</subject><subject>Economic impact</subject><subject>Expert Review</subject><subject>Health aspects</subject><subject>HIV</subject><subject>Human immunodeficiency virus</subject><subject>Humans</subject><subject>Liposomes - chemistry</subject><subject>Medical Law</subject><subject>Micelles</subject><subject>Mycobacterium tuberculosis - drug effects</subject><subject>Nanomedicine - methods</subject><subject>Nanomedicine for Infectious Diseases</subject><subject>Nanoparticles - chemistry</subject><subject>Nanotechnology</subject><subject>Nanotechnology - methods</subject><subject>Patient compliance</subject><subject>Pharmacology/Toxicology</subject><subject>Pharmacy</subject><subject>Tuberculosis</subject><subject>Tuberculosis - drug therapy</subject><subject>Tuberculosis - pathology</subject><issn>0724-8741</issn><issn>1573-904X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNp1kUtPxCAUhYnR6Pj4AW5ME9dVoFDA3WTiKzG6UBN3hNLLTCedotAuZn696IwaEw0LCHzn3ss5CB0TfEYwFueREKx4jonMKVMiX22hEeGiyBVmL9tohAVluRSM7KH9GOcYY0kU20V7BaaFJKUcodt70_ke7KzzrZ8us6bLnoYKgh1aH5t4kT32pofMu6yfQTYOfWa6-vM8mZm2hW4KMRvPwNSHaMeZNsLRZj9Az1eXT5Ob_O7h-nYyvsstK1Sf05IbYXltiaK0LDmmlWBUMiCcV7amFEilKl66qnKQJqaWMcmkEg5T6lRRHKDTdd3X4N8GiL2e-yF0qaWmyQ_CmSzEDzU1Leimc74Pxi6aaPU4uUITWJSJOvuDSquGRWN9B65J978EZC2wwccYwOnX0CxMWGqC9Ucmep2JTpnoj0z0KmlONgMP1QLqb8VXCAmgayCmp2Ro-PnR_1XfAWHtk8s</recordid><startdate>20181101</startdate><enddate>20181101</enddate><creator>Grotz, Estefania</creator><creator>Tateosian, Nancy</creator><creator>Amiano, Nicolas</creator><creator>Cagel, Maximiliano</creator><creator>Bernabeu, Ezequiel</creator><creator>Chiappetta, Diego A.</creator><creator>Moretton, Marcela A.</creator><general>Springer US</general><general>Springer</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20181101</creationdate><title>Nanotechnology in Tuberculosis: State of the Art and the Challenges Ahead</title><author>Grotz, Estefania ; Tateosian, Nancy ; Amiano, Nicolas ; Cagel, Maximiliano ; Bernabeu, Ezequiel ; Chiappetta, Diego A. ; Moretton, Marcela A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c439t-265a7c5dc192266502b74284e155bcd22e1b9b56fbbfe0002c4484897f022f933</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Acquired immune deficiency syndrome</topic><topic>AIDS</topic><topic>Animals</topic><topic>Antitubercular agents</topic><topic>Antitubercular Agents - administration & dosage</topic><topic>Antitubercular Agents - chemistry</topic><topic>Antitubercular Agents - therapeutic use</topic><topic>B cells</topic><topic>Biochemistry</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedical Engineering and Bioengineering</topic><topic>Biomedicine</topic><topic>Development and progression</topic><topic>Drug delivery</topic><topic>Drug Delivery Systems - methods</topic><topic>Drug Discovery - methods</topic><topic>Drug resistance</topic><topic>Drug Resistance, Bacterial</topic><topic>Economic impact</topic><topic>Expert Review</topic><topic>Health aspects</topic><topic>HIV</topic><topic>Human immunodeficiency virus</topic><topic>Humans</topic><topic>Liposomes - chemistry</topic><topic>Medical Law</topic><topic>Micelles</topic><topic>Mycobacterium tuberculosis - drug effects</topic><topic>Nanomedicine - methods</topic><topic>Nanomedicine for Infectious Diseases</topic><topic>Nanoparticles - chemistry</topic><topic>Nanotechnology</topic><topic>Nanotechnology - methods</topic><topic>Patient compliance</topic><topic>Pharmacology/Toxicology</topic><topic>Pharmacy</topic><topic>Tuberculosis</topic><topic>Tuberculosis - drug therapy</topic><topic>Tuberculosis - pathology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Grotz, Estefania</creatorcontrib><creatorcontrib>Tateosian, Nancy</creatorcontrib><creatorcontrib>Amiano, Nicolas</creatorcontrib><creatorcontrib>Cagel, Maximiliano</creatorcontrib><creatorcontrib>Bernabeu, Ezequiel</creatorcontrib><creatorcontrib>Chiappetta, Diego A.</creatorcontrib><creatorcontrib>Moretton, Marcela A.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Pharmaceutical research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Grotz, Estefania</au><au>Tateosian, Nancy</au><au>Amiano, Nicolas</au><au>Cagel, Maximiliano</au><au>Bernabeu, Ezequiel</au><au>Chiappetta, Diego A.</au><au>Moretton, Marcela A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Nanotechnology in Tuberculosis: State of the Art and the Challenges Ahead</atitle><jtitle>Pharmaceutical research</jtitle><stitle>Pharm Res</stitle><addtitle>Pharm Res</addtitle><date>2018-11-01</date><risdate>2018</risdate><volume>35</volume><issue>11</issue><spage>213</spage><epage>22</epage><pages>213-22</pages><artnum>213</artnum><issn>0724-8741</issn><eissn>1573-904X</eissn><abstract>Tuberculosis (TB) remains as the second most-deadly infection right behind the HIV/AIDS. Actually, in 2016, TB incidence was estimated in 10.4 million cases. Although an efficient and low-cost TB pharmacotherapy has been available for the last 50 years, the development of multi- and extra-drug-resistant
Mycobacterium tuberculosis
(Mtb) strains has put on the spot the necessity of improved TB regimens. In this framework, this review article presents the main relevant research outcomes of nanotechnology in TB. The novel delivery systems for antituberculosis drugs have been discussed. Moreover, the active-targeted nanomedicines to the Mtb reservoirs enlighten the possibility to eradicate low-replicant mycobacteria and diminish latent TB. Finally, we present an overview of the TB socio-economic impact and the cost-related features of TB regimens associated with the use of nanoformulations.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>30238168</pmid><doi>10.1007/s11095-018-2497-z</doi><tpages>22</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0724-8741 |
| ispartof | Pharmaceutical research, 2018-11, Vol.35 (11), p.213-22, Article 213 |
| issn | 0724-8741 1573-904X |
| language | eng |
| recordid | cdi_proquest_journals_2110154837 |
| source | Springer Nature |
| subjects | Acquired immune deficiency syndrome AIDS Animals Antitubercular agents Antitubercular Agents - administration & dosage Antitubercular Agents - chemistry Antitubercular Agents - therapeutic use B cells Biochemistry Biomedical and Life Sciences Biomedical Engineering and Bioengineering Biomedicine Development and progression Drug delivery Drug Delivery Systems - methods Drug Discovery - methods Drug resistance Drug Resistance, Bacterial Economic impact Expert Review Health aspects HIV Human immunodeficiency virus Humans Liposomes - chemistry Medical Law Micelles Mycobacterium tuberculosis - drug effects Nanomedicine - methods Nanomedicine for Infectious Diseases Nanoparticles - chemistry Nanotechnology Nanotechnology - methods Patient compliance Pharmacology/Toxicology Pharmacy Tuberculosis Tuberculosis - drug therapy Tuberculosis - pathology |
| title | Nanotechnology in Tuberculosis: State of the Art and the Challenges Ahead |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T02%3A39%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Nanotechnology%20in%20Tuberculosis:%20State%20of%20the%20Art%20and%20the%20Challenges%20Ahead&rft.jtitle=Pharmaceutical%20research&rft.au=Grotz,%20Estefania&rft.date=2018-11-01&rft.volume=35&rft.issue=11&rft.spage=213&rft.epage=22&rft.pages=213-22&rft.artnum=213&rft.issn=0724-8741&rft.eissn=1573-904X&rft_id=info:doi/10.1007/s11095-018-2497-z&rft_dat=%3Cgale_proqu%3EA724210136%3C/gale_proqu%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c439t-265a7c5dc192266502b74284e155bcd22e1b9b56fbbfe0002c4484897f022f933%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2110154837&rft_id=info:pmid/30238168&rft_galeid=A724210136&rfr_iscdi=true |